$53.64
0.88% yesterday
Nasdaq, Sep 18, 10:00 pm CET
ISIN
US76243J1051
Symbol
RYTM
Sector
Industry

Rhythm Pharmaceuticals, Inc. Stock price

$53.64
+6.54 13.89% 1M
+13.04 32.12% 6M
+7.67 16.68% YTD
+29.10 118.58% 1Y
+41.01 324.70% 3Y
+29.51 122.30% 5Y
+23.64 78.80% 10Y
Nasdaq, Closing price Wed, Sep 18 2024
+0.47 0.88%
ISIN
US76243J1051
Symbol
RYTM
Sector
Industry

Key metrics

Market capitalization $3.28b
Enterprise Value $3.21b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 31.57
P/S ratio (TTM) P/S ratio 32.22
P/B ratio (TTM) P/B ratio 83.30
Revenue growth (TTM) Revenue growth 132.57%
Revenue (TTM) Revenue $101.78m
EBIT (operating result TTM) EBIT $-265.58m
Free Cash Flow (TTM) Free Cash Flow $-128.45m
Cash position $319.13m
EPS (TTM) EPS $-4.37
P/E forward negative
P/S forward 26.50
EV/Sales forward 25.96
Short interest 23.91%
Show more

Is Rhythm Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.

Rhythm Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Rhythm Pharmaceuticals, Inc. forecast:

8x Buy
89%
1x Hold
11%

Analyst Opinions

9 Analysts have issued a Rhythm Pharmaceuticals, Inc. forecast:

Buy
89%
Hold
11%

Financial data from Rhythm Pharmaceuticals, Inc.

Jun '24
+/-
%
Net Profit -32 -32
31% 31%
-111%
Depreciation and Amortization 0.39 0.39
28% 28%
1%
Stock Compensation 10 10
17% 17%
36%
Operating Cash Flow -29 -29
29% 29%
-100%
Investments - -
-
-
Dividend Paid - -
-
-
Free Cash Flow -29 -29
29% 29%
-100%

In millions USD.

Don't miss a Thing! We will send you all news about Rhythm Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Rhythm Pharmaceuticals, Inc. Stock News

Neutral
GlobeNewsWire
2 days ago
BOSTON, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that on September 11, 2024, the Compensation & Management Development Committee of Rhythm's Board of Directors granted inducement restricted stock units, or RSU...
Positive
Investors Business Daily
8 days ago
Rhythm Pharmaceuticals is near a buy point after strong sales in the second quarter.
Positive
Investors Business Daily
12 days ago
Biotech stocks have been rallying as funds load up. Five stocks have been outperforming the vast majority in the IBD database.
More Rhythm Pharmaceuticals, Inc. News

Company Profile

Rhythm Pharmaceuticals, Inc. engages in developing and commercializing peptide therapeutics for the treatment of gastrointestinal diseases and genetic deficiencies. It focuses on the treatment for Prader-Willi Syndrome and Pro-Opiomelanocortin deficiency obesity. Its product candidate includes setmelanotide, an MC4R agonist designed to restore impaired MC4R pathway function caused by genetic variants that occur upstream of the MC4R. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.

Head office United States
CEO David Meeker
Employees 226
Founded 2008
Website www.rhythmtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today